In homeostasis, intestinal cell fate is controlled by balanced gradients of morphogen signalling. The Bone Morphogenetic Protein (BMP) pathway has a physiological, pro-differentiation role, predominantly inferred through previous experimental pathway […]» Read more
Sulfation is a conjugation reaction essential for numerous biochemical and cellular functions in mammals. The 3′-phosphoadenosine 5′-phosphosulfate (PAPS) synthase 2 (PAPSS2) is the key enzyme to generate PAPS, which is […]» Read more
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome.
The microbiome directly affects the balance of pro-inflammatory and anti-inflammatory responses in the gut. As microbes thrive on dietary substrates, the question arises whether we can nourish an anti-inflammatory gut […]» Read more
Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.
The effectiveness of µ-opioid receptor (MOPr) agonists for treatment of visceral pain is compromised by constipation, respiratory depression, sedation and addiction. We investigated whether a fentanyl analogue, (±)-N-(3-fluoro-1-phenethylpiperidine-4-yl)-N-phenyl propionamide (NFEPP), […]» Read more
DIETARY GLUTEN INTAKE IS NOT ASSOCIATED WITH RISK OF INFLAMMATORY BOWEL DISEASE IN U.S. ADULTS WITHOUT CELIAC DISEASE.
Diet is thought to play a role in the development of inflammatory bowel disease (IBD), though the relationship between gluten intake and risk of IBD has not been explored. The […]» Read more
Ultrasonography tight control and monitoring in Crohn’s disease during different biological therapies: a multicenter study.
Bowel Ultrasonography (BUS) is a non-invasive tool for evaluating bowel activity in Crohn’s disease (CD) patients. Aim of our multicenter study was to assess whether BUS helps to monitor intestinal […]» Read more
This review summarizes infectious diseases involving the small bowel (SB) with a focus on recent literature related to diagnosis and pathophysiology.Typical symptom for SB infections is diarrhea, mostly self-limiting. Pathogens […]» Read more
Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease.
Small bowel fibrosis is a significant burden on Crohn’s disease patients with limited effective medical treatments that then requires surgery. A better understanding of the molecular mechanisms causing fibrosis and […]» Read more
The Simple Endoscopic Score for Crohn’s disease (SES-CD) is the primary tool for measurement of mucosal inflammation in clinical trials but lacks prognostic potential. We set to develop and validate […]» Read more
Small bowel diseases pose a unique diagnostic and management challenge and often requires tertiary specialist referral. The use of biomarkers may provide a cheap, noninvasive tool to assess the small […]» Read more
Primary sclerosing cholangitis (PSC) is in 70% of cases associated with inflammatory bowel disease. The hypermorphic T108M variant of the orphan G protein-coupled receptor GPR35 increases risk for PSC and […]» Read more
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
Our aim was to explore the risk of infection with all classes of inflammatory bowel disease (IBD) medications and the impact of these medications on the disease course in a […]» Read more
Advances in genomic technologies have led to increasing reports of monogenic inflammatory bowel disease (IBD). However, there has not been a detailed evaluation of the characteristics of the published cases […]» Read more
Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients with Immune-Mediated Inflammatory Diseases.
We conducted a retrospective cohort study to inform the safety of exposure to immunosuppressive and/or biologic agents around conception in expectant fathers with immune-mediated inflammatory diseases (IMIDs) on birth outcomes.Using […]» Read more
Bacterial swarming, a collective movement on a surface, has rarely been associated with human pathophysiology. This study aims to define a role for bacterial swarmers in amelioration of intestinal stress.We […]» Read more
Practical insights into stomas in inflammatory bowel disease: what every healthcare provider needs to know.
Despite advances in medical and surgical therapy in inflammatory bowel disease (IBD) management, intestinal stomas can be needed in a significant proportion of patients. The impact of stomas in patients’ […]» Read more
Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis.
This review addresses the selection of biologic and small molecule therapy for patients with moderate to severe ulcerative colitis (UC). With several new treatment options approved within the past few […]» Read more
Since there is a lack of head-to-head randomized controlled trials, little direction is provided from guidelines on the positioning of biologics for the treatment of Crohn’s disease (CD). This review […]» Read more
Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Inflammatory bowel disease (IBD) is a lifelong condition with no cure. Patients with IBD might experience symptoms of common mental disorders such as anxiety and depression because of bidirectional communication […]» Read more
Anal squamous cell carcinoma is the most common type of anal cancer and is largely associated with anal human papillomavirus infection. The incidence of anal squamous cell carcinoma is increasing, […]» Read more
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We summarize efficacy and safety data of tofacitinib 5 or 10 mg twice daily […]» Read more
Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
This study compared pharmacokinetics, symptomatic and endoscopic efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab biosimilar CT-P13 (CT-P13 SC) versus intravenous CT-P13 (CT-P13 IV) in inflammatory bowel […]» Read more
Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease.
A large unmet therapeutic need exists in inflammatory bowel diseases (IBD). Inhibition of interleukin (IL)-6 appears to be effective, but the therapeutic benefit of a complete IL-6/IL-6R blockade is limited […]» Read more
Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease.
Clostridioides difficile infection (CDI) may complicate the course of ulcerative colitis and Crohn’s disease. The clinical presentation of CDI in this population is often atypical, and patients may experience exacerbations […]» Read more
The IM-UNITI study and long-term extension (LTE) evaluated the long-term efficacy, safety, and immunogenicity of subcutaneous ustekinumab maintenance therapy in patients with Crohn’s disease (CD). Here we report final results […]» Read more
Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis – NICE guidance.
Tofacitinib is an oral, Janus kinase (JAK) molecule, which selectively inhibits Janus-associated tyrosine kinases JAK1 and JAK3. It has already shown efficacy in the treatment of rheumatoid arthritis and the […]» Read more
Inflammatory bowel disease psychological support pilot reduces inflammatory bowel disease symptoms and improves psychological wellbeing.
This prospective service evaluation aimed to determine if integrated psychological support for patients with inflammatory bowel disease (IBD) enhanced outcomes. 75 patients were assessed and treated by a specialist liaison […]» Read more
An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials.
Histopathology is an emerging treatment target in ulcerative colitis (UC) clinical trials. We aim to provide guidance on standardizing biopsy collection protocols, identifying optimal evaluative indices, and defining thresholds for […]» Read more
Ulcerative colitis is the most frequent type of inflammatory bowel disease and is characterized by colonic epithelial cell damage. Although involvement of autoimmunity has been suggested in ulcerative colitis, specific […]» Read more
Gastrointestinal Infection and Risk of Microscopic Colitis: A Nationwide Case-Control Study in Sweden.
Gastrointestinal infections have been linked to changes in the composition and function of gut microbiome and development of inflammatory bowel diseases. We therefore sought to examine the relationship between gastroenteritis […]» Read more